Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

We develop DNA sequencing and array-based life sciences technologies to enable boundless research discovery and personalized health. Our products help pioneer advances in oncology, genetic and infectious diseases, reproductive health, and beyond.

Illumina sequencing technology, sequencing by synthesis (SBS), is a widely adopted next-generation sequencing (NGS) technology worldwide. Illumina instruments and reagents use a proprietary method that detects single bases as they are incorporated into growing DNA strands with massively parallel capabilities.

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.

Nov 2, 2024 · Illumina sequencing is one of the most widely used next-generation sequencing (NGS) technology that uses sequencing by synthesis to detect individual DNA bases as they are added to a growing strand. It uses advanced instruments capable of processing millions of DNA sequences at the same time.

Feb 19, 2025 · Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale.

Apr 3, 2023 · We’re celebrating 25 years of growth by looking at 25 of the greatest impacts that Illumina technology has made to date. 1. We advanced sequencing chemistry to be faster, more accurate, and more stable. When we launched the Genome Analyzer in 2007, we introduced the world to Illumina sequencing by synthesis (SBS) chemistry.

Jan 13, 2025 · Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery.

Feb 18, 2014 · In the coming age of genomic medicine, Illumina is poised to be what Intel was to the PC era—the dominant supplier of the fundamental technology.

Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.